US-based diagnostics company Alere has obtained the in-vitro diagnostic (IVD) CE mark in Europe for its new Alere Reader, a diagnostic analyser.

The device has been designed to be used with both point-of-care and laboratory settings.

The physicians, lab technicians and other healthcare personnel can insert test cards into the Alere Reader at the read time which then detects, identifies and examines the completed lateral flow assay.

"By ensuring the accuracy of test results, no matter who interprets them, the Alere Reader helps support key goals of regulatory and health stakeholders."

The Alere Reader features an intuitive touch screen which displays the results of the test card inserted.

The results can be immediately connected to patient electronic medical records and back-end information systems, or can be printed.

Additionally, the device features an automated function which further validates the quality control run on the results, thereby instilling confidence in the users.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Alere infectious disease global president Avi Pelossof said: "The Alere Reader improves what is already a leading rapid testing solution for community-acquired pneumonia (CAP) in Europe in two key ways: by eliminating operator subjectivity and by instantaneously connecting BinaxNOW test results with laboratory and hospital information management systems.

 "By ensuring the accuracy of test results, no matter who interprets them, the Alere Reader helps support key goals of regulatory and health stakeholders; in addition, by utilising the Alere Reader at the point-of-care, providers can obtain the most accurate results within an actionable timeframe so they can administer the right treatment quickly.

"We are committed to populating the Alere Reader with a comprehensive menu of rapid tests so these benefits can be experienced in any setting where expedient and accurate tests are demanded."

The company is planning to add extra assays designed to detect respiratory and healthcare associated infections to the Alere Reader menu.